Source: ACCESSWIRE From: yahoo.com AIM ImmunoTech Inc., (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases – such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) – announced progress toward the opening of Roswell Park Comprehensive Cancer Center’s Phase 1 clinical study of chemokine modulation plus neoadjuvant chemotherapy in …
Context Therapeutics and SOLTI launch ONAWA: a Window of Opportunity Study in Breast Cancer with Apristor
Source: Business Wire From: manchestertimes.com Context Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing medicines for hormone driven cancers, today announced a clinical collaboration with SOLTI, a leading collaborative and academic group in Spain dedicated to clinical and translational research in breast cancer. This clinical collaboration, being supported by Context and sponsored by SOLTI, is a window of opportunity study …
Newly Approved Targeted Therapy Paves the Way for Patients With Advanced Bladder Cancer
By: Katie Kosko From: curetoday.com Patients with advanced bladder cancer and a specific gene mutation have a promising new treatment option, according to phase 2 study findings published in the New England Journal of Medicine. The international trial was led by researchers from The University of Texas MD Anderson Cancer Center and included 99 patients with metastatic urothelial carcinoma or …
Ipsen and Servier announce initial Phase II/III clinical data evaluating investigational liposomal irinotecan (ONIVYDE®) as a second-line treatment for small cell lung cancer
Source: Business Wire From: yahoo.com – 44% of patients achieved a response and nearly half (48%) maintained disease control at week 12 (efficacy as secondary endpoint) – – Treatment emergent adverse events Grade 3 or higher were reported by 10 of 25 patients (safety as primary endpoint) – Ipsen (Euronext: IPN; ADR: IPSEY) and Servier announced today initial safety and …
World’s First Clinical Trial to Ease Pain of Cancer Patients
Dr. Yaacov Richard Lawrence, a London-born and educated doctor, is part of a unique team of Radiation Oncology specialists at Sheba Medical Center, conducting the world’s first clinical trial and study of targeted radiation treatments into the solar plexus (the main abdominal artery), to relieve excruciating pain and prolong the lives of critically ill pancreatic cancer patients. Other members of the …
High Marks for Proton-Beam RT in Breast Cancer
By: Charles Bankhead From: medpagetoday.com Women with locally advanced breast cancer requiring regional lymph node irradiation had similar disease control with less toxicity with proton-beam radiation therapy (RT) as compared with historical patients treated with conventional radiotherapy, investigators in a small prospective study reported. The 69 evaluable patients had a 5-year locoregional failure rate of 1.5% and 5-year overall survival …
Oncoceutics Announces FDA Acceptance of Investigational New Drug Application for Phase I Trial of ONC206
Oncoceutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for ONC206, allowing the first-in-human trial of the compound. ONC206 is the first of the family of drug candidates, which we call “imipridones”, that possess the same core chemical structure as ONC201. The first clinical trial for ONC206 in adults …
Another myeloma drug with same target as CAR-Ts shows successful Phase II results
By: Alaric DeArment From: medcitynews.com Without providing details, GlaxoSmithKline said its trial of BCMA-targeting belantamab mafodotin was positive. The company plans to submit for regulatory approvals later this year – potentially ahead of bluebird and Celgene’s expected filing next year for the CAR-T bb2121. A Phase II study of a GlaxoSmithKline drug to treat the blood cancer multiple myeloma has …
Alpelisib Arrives as New Targeted Option for Breast Cancer Subgroup
By: Brittany Lovely From: onclive.com In May 2019, the FDA approved alpelisib (Piqray) in combination with fulvestrant for the treatment of postmenopausal women and men with hormone receptor (HR)–positive, HER2-negative PIK3CA-mutated advanced or metastatic breast cancer, making it the first targeted therapy in this setting with a predictive biomarker. Overall, approximately 70% of breast cancers are classified as HR positive/HER2 …
Lumicell Completes Enrollment of Phase C Feasibility Trial for Breast Cancer Surgical Guidance Solution
From: biospace.com Lumicell, Inc., an innovation leader in image guided cancer surgery, today announced that it has completed enrollment in its Phase C feasibility clinical trial of the Lumicell Imaging System for breast cancer. With results from the Phase C feasibility trial expected in late 2019, Lumicell expects to begin the pivotal trial by the end of 2019 before applying …